Intractable & Rare Diseases Research
Online ISSN : 2186-361X
Print ISSN : 2186-3644
ISSN-L : 2186-3644
Case Report
Rituximab use for refractory anti-HMGCR immune-mediated necrotizing myopathy: A case report
Sonia GuptaAmandeep RakhraVinay ThallapallyJoseph Nahas
Author information
JOURNALS FREE ACCESS

2021 Volume 10 Issue 2 Pages 122-125

Details
Abstract

Immunosuppression is the cornerstone therapy for anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) myopathy. Typical immunosuppressants such as corticosteroids, methotrexate, and azathioprine have been used in conjunction with removal of the offending agent, yet the use of rituximab is more limited in this type of myopathy. Reported here is a case of a patient who responded well to rituximab (RTX) after the standard immunosuppressants had failed. This case illustrates the importance of further studies to evaluate the role of RTX in anti-HMGCR myopathy.

Information related to the author
© 2021 International Research and Cooperation Association for Bio & Socio-Sciences Advancement
Previous article Next article
feedback
Top